Valneva SE (EPA:VLA)

Market Cap	674.24M +92.0%
Revenue (ttm)	179.91M +13.5%
Net Income	-102.16M
EPS	-0.61
Shares Out	173.42M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	470,630
Average Volume	967,134
Open	3.962
Previous Close	3.990
Day's Range	3.888 - 4.022
52-Week Range	2.250 - 5.415
Beta	1.19
RSI	44.53
Earnings Date	Mar 1, 2026

About Valneva SE

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease ca...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Employees: 700
• Stock Exchange: Euronext Paris
• Ticker Symbol: VLA

Financial Performance

In 2024, Valneva SE's revenue was 169.58 million, an increase of 10.32% compared to the previous year's 153.71 million. Losses were -12.25 million, -87.93% less than in 2023.